Quick answer
Diabetes does not automatically disqualify a commercial driver. For insulin-treated diabetes, the driver must provide a timely MCSA-5870 completed by the treating clinician, and the Certified Medical Examiner applies 49 CFR 391.46, reviews stability, control, complications, severe hypoglycemia, and electronic glucose records, and may certify for no more than 12 months. Non-insulin-treated diabetes is evaluated under the general standards and individualized safety risk.
Separate insulin-treated from non-insulin-treated diabetes
The regulatory pathway depends on treatment. Drivers using insulin for control fall under 49 CFR 391.46. Drivers managed without insulin do not use that specific process, but the examiner still evaluates control, complications, medication effects, hypoglycemia risk, and functional ability. Do not apply the insulin rule merely because insulin was used historically; establish the current regimen and clinical context.
Use Form MCSA-5870 correctly
For an insulin-treated driver, the treating clinician who manages and prescribes insulin completes MCSA-5870. The Certified Medical Examiner must receive the form within 45 days of its completion. Review it for completeness, treatment stability, glucose-monitoring records, severe hypoglycemic episodes, and complications. The form supplies essential clinical information but does not certify the driver; the examiner makes the federal decision.
Review electronic glucose records and control
The rule generally requires at least three months of electronic blood-glucose self-monitoring records generated by a compliant device for the maximum 12-month certification. When less than three months is available, the regulation limits how the examiner may proceed. Consider patterns, severe lows, awareness, adherence, and whether monitoring matches the treating clinician’s plan. Hemoglobin A1c is informative but is not a standalone pass-fail threshold.
Evaluate complications and severe hypoglycemia
Assess retinopathy, neuropathy, nephropathy, cardiovascular disease, cognitive effects, foot problems, and other complications that may independently affect qualification. Severe non-proliferative or proliferative diabetic retinopathy is a permanent disqualifying condition under the insulin-treated standard. After a severe hypoglycemic episode, the driver must stop operating and follow the treating-clinician evaluation and new-form process required by the rule.
Document the individualized decision
Record treatment type, MCSA-5870 timing, monitoring data, complications, hypoglycemia history, examination findings, and the reasoning for the outcome and interval. Insulin-treated certification may not exceed 12 months. For non-insulin-treated diabetes, choose the interval based on the overall risk and applicable standards rather than an automatic policy. Educate the driver about reporting material changes without practicing beyond the examiner role.
Frequently Asked Questions
Does insulin automatically disqualify a driver?
No. Qualified insulin-treated drivers may be certified under 49 CFR 391.46.
How recent must MCSA-5870 be?
The examiner must receive it within 45 days after the treating clinician signs and dates it.
Is a specific A1c required by regulation?
The rule does not establish a single A1c pass-fail cutoff; evaluate the complete evidence.
What is the maximum certificate for insulin-treated diabetes?
No more than 12 months, assuming all requirements are met.
Key Takeaways
- Diabetes does not automatically disqualify a commercial driver.
- Federal Diabetes exemptions no longer exist as of the 2018 Diabetes Rule which allows medical examiners a protocol to certify ITDM drivers directly.